A retrospective Aliskiren and Losartan study in non-diabetic chronic kidney disease

Table 1 Comparing demographic and clinical profile of patients treated with combined dose Aliskerin and Angiotensin receptor blockers, Aliskerin alone and high dose Angiotensin receptor blockers

	Combined Aliskerin and ARB	Aliskerin	High dose ARB	1P value
	n= 49	n= 46	n= 48
Sex (F : M)	16:33	22:24	23:25	NS
Age at biopsy (yr)	58 ± 12	57 ± 12	60 ± 11	NS
Duration of Trial (mo)	37 ± 1	36 ± 1	36 ± 1	NS
Hypertension (Yes : No)	16:15	15:31	17:31	NS
Serum Creatinine (µmol/L)
Baseline	142 ± 39	142 ± 40	139 ± 32	NS
Year 3	159 ± 53 (P = 0.001)	161 ± 54 (P < 0.001)	150 ± 47 (P = 0.015)	NS
eGFR (mL/min)
Baseline	49 ± 19	48 ± 14	48 ± 14	NS
Year 3	44 ± 18 (P < 0.001)	42 ± 15 (P < 0.001)	45 ± 15 (P = 0.002)	NS
Decrease in eGFR (mL/min per year)	1.8 ± 2.5	2.0 ± 3.0	1.0 ± 2.1	P = 0.119
Urinary Protein (gm/d)
Baseline	0.7 ± 0.6	0.8 ± 0.9	0.6 ± 0.7	NS
Year 3	0.5 ± 0.8 (P = 0.002)	0.6 ± 0.7 (P = 0.043)	0.3 ± 0.3 (P < 0.001)	P = 0.007
Blood Pressure (mmHg)
Systolic before	132 ± 12	135 ± 10	132 ± 12	NS
Systolic after	127 ± 10 (P < 0.001)	130 ± 9 (P < 0.001)	128 ± 11 (P < 0.001)	NS
Diastolic before	84 ± 7	85 ± 6	84 ± 7	NS
Diastolic after	82 ± 5 P = 0.040	83 ± 6 P = 0.084	83 ± 6 P = 0.361	NS
Distribution of CKD at baseline
CKD 1	1	0	0	0.465
CKD 2	8	5	4
CKD 3	40	41	44
Distribution of CKD at year 3				0.606
CKD 1	1	0	0
CKD 2	8	7	5
CKD 3	28	26	34
CKD 4	12	13	9
Non-ESRF	49	46	48	NS
ESRF	0	0	0
Improvement in eGFR
Yes	12	15	15	0.645
No	37	31	33

¹P value either from chi-square test or analysis of variance test comparing the 3 groups. M: Male; F: Female; IQR: Interquartile Range, 25^th percentile-75^th percentile, continuous data are presented as mean ± SD or median (IQR) and categorical data as count (%); eGFR: estimated Glomerular Filtration Rate; CKD: Chronic Kidney Disease; ARB: Angiotensin receptor Blockers; ESRF: End-stage renal failure; NS: No significant.